SYRS - Syros Pharmaceuticals Inc Stock Price, Fair Value and News

5.04USD-0.06 (-1.18%)Delayed

Market Summary

USD5.04-0.06

Delayed

-1.18%

SYRS Stock Price

View Fullscreen

SYRS RSI Chart

SYRS Valuation

Market Cap

133.3M

Price/Earnings (Trailing)

-0.81

Price/Sales (Trailing)

13.42

Price/Free Cashflow

-1.21

SYRS Price/Sales (Trailing)

SYRS Profitability

Return on Equity

-987.72%

Return on Assets

-97.86%

Free Cashflow Yield

-82.49%

SYRS Fundamentals

SYRS Revenue

Revenue (TTM)

9.9M

Rev. Growth (Yr)

-88.71%

Rev. Growth (Qtr)

-89.73%

SYRS Earnings

Earnings (TTM)

-164.6M

Earnings Growth (Yr)

-1.2K%

Earnings Growth (Qtr)

-60.39%

Breaking Down SYRS Revenue

Last 7 days

11.0%

Last 30 days

-13.7%

Last 90 days

-26.6%

Trailing 12 Months

68.6%

How does SYRS drawdown profile look like?

SYRS Financial Health

Current Ratio

3.95

Debt/Equity

2.07

Debt/Cashflow

-3.17

SYRS Investor Care

Shares Dilution (1Y)

30.31%

Diluted EPS (TTM)

-5.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	13.6M	12.4M	11.2M	9.9M
2022	24.1M	25.2M	23.4M	14.9M
2021	17.5M	19.5M	21.4M	23.5M
2020	3.9M	6.6M	9.9M	15.1M
2019	2.1M	2.2M	2.4M	2.0M
2018	370.0K	745.0K	1.2M	2.0M
2017	684.0K	1.1M	1.4M	1.1M
2016	0	0	0	317.0K
2015	0	0	0	317.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Syros Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 03, 2024	roth david	sold	-51,732	4.95	-10,451	chief medical officer
Apr 02, 2024	roth david	sold	-747	4.9803	-150	chief medical officer
Apr 01, 2024	haas jason	sold (taxes)	-24,227	5.12	-4,732	chief financial officer
Apr 01, 2024	roth david	sold (taxes)	-24,227	5.12	-4,732	chief medical officer
Apr 01, 2024	chee conley	sold (taxes)	-17,920	5.12	-3,500	president & ceo
Apr 01, 2024	simonian nancy a	sold (taxes)	-71,946	5.12	-14,052	-
Apr 01, 2024	stephens kristin	sold (taxes)	-21,596	5.12	-4,218	chief development officer
Mar 31, 2024	stephens kristin	acquired	-	-	13,666	chief development officer
Mar 31, 2024	haas jason	acquired	-	-	15,333	chief financial officer
Mar 31, 2024	roth david	acquired	-	-	15,333	chief medical officer

Which funds bought or sold SYRS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	1,000	1,000	-%
Apr 24, 2024	Assenagon Asset Management S.A.	added	576	713,732	909,495	-%
Apr 24, 2024	PSI Advisors, LLC	unchanged	-	-31.00	70.00	-%
Apr 23, 2024	FIFTH THIRD BANCORP	unchanged	-	-315	690	-%
Apr 17, 2024	Clarius Group, LLC	unchanged	-	-45,433	99,617	0.01%
Apr 15, 2024	Sound Income Strategies, LLC	unchanged	-	-185	407	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	4,205	8,530	-%
Mar 11, 2024	VANGUARD GROUP INC	added	44.8	3,871,530	5,957,890	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	349	3,313,430	3,734,230	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	unchanged	-	86,000	176,000	-%

Are Funds Buying or Selling SYRS?

Are funds buying SYRS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SYRS

No. of Funds

Unveiling Syros Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	blue owl capital holdings lp	5.74%	1,493,252	SC 13G
Feb 13, 2024	ally bridge medalpha master fund l.p.	2.6%	570,976	SC 13G/A
Feb 13, 2024	bain capital life sciences fund ii, l.p.	9.99%	2,749,808	SC 13G/A
Feb 13, 2024	avidity partners management lp	9.9%	2,662,206	SC 13G/A
Feb 09, 2024	artal international s.c.a.	9.9%	3,568,842	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	9.99%	2,623,984	SC 13G/A
Jan 02, 2024	point72 asset management, l.p.	5.7%	1,471,771	SC 13G
Dec 26, 2023	samsara biocapital, l.p.	9.5%	2,493,541	SC 13D/A
Oct 20, 2023	samsara biocapital, l.p.	7.4%	1,588,564	SC 13D
Feb 14, 2023	bain capital life sciences fund ii, l.p.	9.99%	2,124,694	SC 13G/A

Recent SEC filings of Syros Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 12, 2024	PRE 14A	PRE 14A
Apr 05, 2024	4	Insider Trading
Apr 03, 2024	144	Notice of Insider Sale Intent
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	144	Notice of Insider Sale Intent
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to Syros Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Syros Pharmaceuticals Inc News

Latest updates

Syros Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-89.7%	387	3,762	2,833	2,954	3,423	3,891	6,276	5,467	7,802	5,697	5,162	4,827	5,698	3,828	3,188	2,379	508	558	462	454	893
Operating Expenses	-28.3%	27,527	38,398	36,833	36,166	35,243	43,345	40,045	32,120	33,226	32,608	31,306	25,768	34,918	22,825	19,929	19,718	20,679	20,947	20,670	17,427	19,500
S&GA Expenses	-24.2%	5,888	7,764	7,225	7,405	7,329	8,076	6,945	6,949	6,431	5,346	5,520	5,739	5,892	5,151	5,133	5,149	6,402	5,016	5,195	4,865	4,372
R&D Expenses	-24.0%	21,504	28,280	29,608	28,761	27,914	25,759	33,100	25,171	26,795	27,262	25,786	20,029	29,026	17,674	14,796	14,569	14,277	15,931	15,475	12,562	15,128
Interest Expenses	2.0%	1,329	1,303	1,278	1,217	1,126	1,051	981	976	987	984	969	967	541	493	487	271	20.00	21.00	23.00	8.00	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.00	-	-	-	-	-
Net Income	-60.4%	-64,384	-40,143	-36,258	-23,789	-4,774	-30,253	-34,481	-25,146	-23,813	-26,027	-22,490	-14,228	-30,130	-19,486	-17,196	-17,226	-19,729	-19,793	-19,455	-16,461	-18,032
Net Income Margin	-76.3%	-16.56*	-9.40*	-7.66*	-6.84*	-6.36*	-4.85*	-4.34*	-4.04*	-3.69*	-4.34*	-4.42*	-4.62*	-	-	-	-	-	-	-	-	-
Free Cashflow	41.6%	-18,600	-31,858	-22,385	-37,136	-31,757	-36,115	-26,289	-30,145	-23,214	-28,437	-26,882	-22,252	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	13.8%	168	148	181	205	244	285	126	152	183	208	234	110	213	133	148	161	150	144	152	88.00	107
Current Assets	18.3%	145	123	153	174	211	252	92.00	116	137	153	186	110	179	99.00	112	126	115	111	124	78.00	102
Cash Equivalents	24.3%	140	112	115	105	167	15.00	59.00	70.00	95.00	119	164	225	174	93.00	109	117	45.00	33.00	102	22.00	50.00
Net PPE	-4.2%	7.00	8.00	10.00	11.00	11.00	12.00	12.00	13.00	13.00	13.00	14.00	14.00	14.00	15.00	15.00	16.00	15.00	11.00	5.00	4.00	4.00
Current Liabilities	29.2%	37.00	28.00	28.00	24.00	31.00	38.00	39.00	28.00	32.00	30.00	28.00	6.00	29.00	28.00	23.00	20.00	24.00	23.00	15.00	15.00	20.00
Long Term Debt	-12.3%	35.00	39.00	41.00	39.00	41.00	41.00	34.00	39.00	40.00	40.00	40.00	40.00	40.00	20.00	20.00	20.00	-	-	-	-	-
LT Debt, Current	299.9%	7.00	2.00	-	2.00	-	-	7.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-12.3%	35.00	39.00	41.00	39.00	41.00	41.00	34.00	39.00	40.00	40.00	40.00	40.00	40.00	20.00	20.00	20.00	-	-	-	-	-
Shareholder's Equity	-54.1%	17.00	36.00	73.00	107	128	129	31.00	63.00	85.00	106	130	150	91.00	46.00	62.00	19.00	79.00	95.00	112	64.00	79.00
Retained Earnings	-9.8%	-722	-658	-618	-582	-558	-553	-523	-488	-463	-439	-413	-136	-377	-346	-327	-310	-292	-273	-253	-234	-217
Additional Paid-In Capital	6.4%	739	695	691	688	686	683	554	552	549	546	544	239	468	393	390	387	372	368	365	298	296
Shares Outstanding	27.6%	26.00	21.00	21.00	20.00	20.00	9.00	6.00	6.00	6.00	6.00	6.00	6.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	59.00	-	-	-	56.00	-	-	-	311	-	-	-	442,689	-	-	-	351,070	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	41.7%	-18,562	-31,858	-22,386	-36,901	-31,083	-35,787	-26,178	-30,017	-22,969	-28,127	-26,454	-21,990	-29,924	-15,255	-12,431	246	-10,603	-11,224	-18,099	-20,327	-13,812
Share Based Compensation	-47.2%	1,720	3,255	2,814	2,645	2,903	2,955	2,689	2,863	2,875	2,096	2,453	2,930	3,030	2,723	2,727	2,459	3,216	2,389	2,355	1,879	1,633
Cashflow From Investing	-94.7%	1,522	28,640	32,923	-25,748	37,721	6,192	15,889	7,383	-245	-17,301	-34,845	-262	-29.00	-522	4,012	43,203	16,953	-57,140	32,682	-4,229	20,037
Cashflow From Financing	867700.0%	43,380	-5.00	140	-53.00	-10,703	142,064	-223	-93.00	96.00	-67.00	72.00	70,410	110,804	236	220	31,693	1,089	-12.00	65,028	-115	137

SYRS Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 9,936	$ 14,880
Operating expenses:
Research and development	108,153	111,944
General and administrative	28,282	29,299
Transaction related expenses		9,510
Restructuring (Note 14)	2,489
Total operating expenses	138,924	150,753
Loss from operations	(128,988)	(135,873)
Interest income	6,816	2,132
Interest expense	(5,127)	(4,134)
Change in fair value of warrant liabilities	(37,275)	43,221
Net loss applicable to common stockholders	$ (164,574)	$ (94,654)
Net loss per share applicable to common stockholders - basic	$ (5.81)	$ (7.49)
Net loss per share applicable to common stockholders - diluted	$ (5.81)	$ (7.49)
Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic	28,325,779	12,631,968
Weighted-average number of common shares used in net loss per share applicable to common stockholders - diluted	28,325,779	12,631,968

SYRS Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 139,526	$ 167,467
Marketable securities		34,837
Unbilled receivable		1,694
Prepaid expenses and other current assets	5,454	7,394
Total current assets	144,980	211,392
Property and equipment, net	7,298	11,353
Other long-term assets	1,592	5,348
Restricted cash	2,119	3,086
Right-of-use asset – operating lease	12,185	13,231
Right-of-use assets – financing leases		76
Total assets	168,174	244,486
Current liabilities:
Accounts payable	11,544	6,411
Accrued expenses	16,146	17,966
Deferred revenue		4,330
Financing lease obligations		65
Operating lease obligation, current portion	2,324	2,006
Debt, current portion	6,667
Total current liabilities	36,681	30,778
Operating lease obligation, net of current portion	18,528	20,851
Warrant liabilities	61,747	24,472
Debt, net of debt discount, net of current portion	34,556	40,649
Commitments and contingencies (See Note 11)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2023 and December 31, 2022; 0 shares issued and outstanding at December 31, 2023 and December 31, 2022
Common stock, $0.001 par value;70,000,000 shares authorized at December 31, 2023 and December 31, 2022; 26,448,678 and 20,263,116 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	26	20
Additional paid-in capital	739,443	685,847
Accumulated other comprehensive income		102
Accumulated deficit	(722,807)	(558,233)
Total stockholders' equity	16,662	127,736
Total liabilities and stockholders' equity	$ 168,174	$ 244,486

About Syros Pharmaceuticals Inc

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Nancy A. Simonian M.D.
WEBSITE	syros.com
INDUSTRY	Biotechnology
EMPLOYEES	117

Syros Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Syros Pharmaceuticals Inc? What does SYRS stand for in stocks?

SYRS is the stock ticker symbol of Syros Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Syros Pharmaceuticals Inc (SYRS)?

As of Fri Apr 26 2024, market cap of Syros Pharmaceuticals Inc is 133.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SYRS stock?

You can check SYRS's fair value in chart for subscribers.

What is the fair value of SYRS stock?

You can check SYRS's fair value in chart for subscribers. The fair value of Syros Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Syros Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SYRS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Syros Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether SYRS is over valued or under valued. Whether Syros Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Syros Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SYRS.

What is Syros Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, SYRS's PE ratio (Price to Earnings) is -0.81 and Price to Sales (PS) ratio is 13.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SYRS PE ratio will change depending on the future growth rate expectations of investors.